|
|||||||||||||||
|
||||||||||||||||||
Data:2009-12-12 2:34
Source: Guangdong Cod Author: Wu is pleased to
Study site 1: Yueyang Xingchang is now 60% owned subsidiary - Chongqing Kang Wei, investment 50 million yuan, which lasted seven years, a new class of bio-medicine countries - recombinant human Helicobacter pylori vaccine (ie stomach vaccine) , has completed all the clinical trials of new drugs will soon receive the certificate. Chongqing Kang Wei developed stomach vaccines belong to the state Class ?new biological products, there is no similar products sold at home and abroad, is the world's first to enter the clinical stage ?gastric vaccines, and clinical trials will soon end. Than the similar products abroad, leading 2-3 years, 4-5 years than the domestic counterparts ahead of time. According to "Drug Registration Regulations" requirement, the vaccine if the access to new drug certificate, will enjoy the state of new drugs for type ?protection policy: Since the drug into the monitoring period (from 5 years from the date of approval) from the date no longer accepted other applicants, applications for registration of the same species; has been accepted but not yet ratified to conduct clinical trials of drugs to other applicants for the same species, it should be returned to the applicant; not to approve the monitoring of other businesses during the production and import of new drugs. Once the drug in Chongqing Kang Wei received the certificate, will have four years of market exclusivity.
study site 2: National stomach in patients with nearly 300 million people, ranking first in the world. 50-70% of our country's high infection rate and an annual result in 30 million people living with the grave situation of the death of gastric cancer, it has been gradually recognized the serious harm of human Helicobacter pylori and the stomach as a universal vaccine-based immunization projects the need for the potential demand would be 5-6 million copies. By 12 years of consideration, the market demand could reach 5,000 million years, who were present, a course of antibiotics, stomach needs about 1,000 yuan, and easy to relapse; while drug prices in the vaccine is only 100-200 yuan, and less recurrence. If the development of pre-, 1 / 10 of people using the vaccine, it could bring 500 million yuan in sales revenue!
Research Point 3: The company estimated that during the market development, plant and public works were copies of the annual 30 million design and construction, equipment by 10 million people were / year to buy to build, to the Zhuhai-based company's costs and investment environment in terms of total investment in the 8000-9000 yuan, total profit could reach 2-4 billion years, according to equity ratio of net profit of 1.14-2.28 billion. Long-term perspective, new drugs will bring huge benefits to listed companies, and unlimited imagination, if the stomach as a universal vaccine based immunization projects, the market will be huge!
Study site 4: At present, the same type of biological vaccine Tiantan Biological Products of Chongqing beer and have a better market performance, dynamic price-earnings ratio were more than 40 times, and the present Chongqing Beer hepatitis B vaccine has just entered a phase ?clinical and Yueyang Xingchang of stomach vaccine Phase ?clinical field work has ended, compared with Chongqing Brewery is expected to as early as 2-3 years in time, get the production license. Although they are all risk investment, but we think the risk of Yueyang Xingchang smaller.
Study site 5: Estimated 06,07,08-year earnings per share were 0.201,0.224,0.945 yuan, performance explosive growth in 2008, a reasonable valuation of 18 yuan now trading just Suliang broken roof, there are still afternoon pulled up space!
Historical Information: Yueyang Xingchang (000,819): dark horse bargain-hunting is not involved in petrochemical shares changed July 8, 2006
Source: China Investment securities Authors: Kou Jianxun
Yueyang Xingchang (000,819) equity structure Reaching Idea Yueyang Xingchang (000,819) is an important member of the Department of Sinopec Group, China's Sinopec Changling Refining & Chemical Co., Ltd. is the second largest circulation of its shareholders, holding company of state-owned shares of 45.45 million shares, up 27.52 percent stake. And the company's largest shareholder Yueyang long lienhsing length Enterprise Group, holds 4616 shares of corporate stock, compared to just 27.95 percent stake. Thus, the company's top two shareholders holding the number of very close, with the difference of only 71 million shares, shareholding ratio was less than 1%, a special ownership structure the company generated a great stake in the possibility of disputes . Top ten shareholders of the company's long-Lian Chang Lian Technology Association staff, long staff of universities and Yueyang long Lian Lian Changqing trade companies are subordinate to China Petrochemical Corporation, the Chief Changling Refining & Chemical Co., the company's collective enterprises. Therefore, China Petrochemical Corporation, through indirect holding control of the company's 4887 million stake in the company's underlying real controller. Sinopec, as the aircraft carrier ship in the state-owned central enterprises, its re-listing of large-scale privatization is expected to substantial increase in the market for the second batch of Sinopec's assets, the expectations have become more strongly integrated, Yueyang Xingchang's petrochemical industry as a high-quality assets, it is highly likely to become the next acquisition target Sinopec.
High-tech bio-pharmaceutical + real estate
The company also strongly involved in high-tech bio-pharmaceutical field, and with the Third Military Medical University Chun biotechnology company co-founded biotechnology company, its holding 60% of Chongqing Kang health materials Technology Co., Ltd. research and development, production and the country a class of drug "people Helicobacter pylori bivalent subunit vaccine adjuvant molecule "(stomach vaccine) for the treatment of stomach caused by Helicobacter pylori. The second-phase clinical trials on-site work has been completed, experimental report is being prepared to do to prepare for Phase III clinical work of the project, once the smooth realization of industrialization, the company will bring new profit growth point in China, there are currently 80% of people with stomach problems, its huge market share and the benefits you can imagine! Very great potential for further development; the same time, more noteworthy is that the sea created a subsidiary, Hunan Science and Technology Co., Ltd. (97% stake) Development of Changsha, Huang Xing Road, Causeway Bay Plaza real estate projects, construction area of 103,000 square meters, the main works had been All cap.
The best haven for two major capital market, the index in the adjustment cases, the unused shares of big money into the best safe haven, but also because a lot of stocks are not stocks instead continuous upside. We introduce Yueyang Xingchang (000,819) Equity less stock more likely to have pulled up the situation may be more feasible. Trend, the stock has been since the previous adjustments, volume shrinking, showing that the unit short kinetic energy is nearly depleted, the energy in the short side after the impending disappearance of the retaliatory counterattack. At the same time, the Unit has been an instant hit limit down Monday, but was immediately swept up generous list, showing that the main unit a strong desire to support the market. Previous high of 11.5 yuan in close proximity, in separate ways the strong funding under the care of, I believe that the shares would soon be reached, investors bought on dips.
